Article Text

Download PDFPDF

570 IL-15/IL-15Rα heterodimeric complex as cancer immunotherapy in murine breast cancer models
  1. Siqi Guo1,
  2. Ronald Smeltz Smeltz2,
  3. Anthony Nanajian1 and
  4. Richard Heller3
  1. 1Old Dominion University, Virginia Beach, VA, USA
  2. 2Virginian Commonwealth University, Richmond, VA, USA
  3. 3University of South Florida, Tampa, FL, USA


Background Interleukin 15 (IL-15) has been evaluated as a potential treatment for solid tumors in clinical trials, but the effectiveness of systemic IL-15 administration as a monotherapy has not been realized. IL-15 receptor alpha (IL-15Rα) can stabilize IL-15 and enhance its bioactivity. The goal of this study was to examine the activity of IL-15/IL-15Rα complex (IL-15cx) to CD8+ T cells and evaluate its potential efficacy in murine breast cancer models.

Methods The bioactivity of IL-15cx to CD8 T cells was assessed by ex vivo and in vivo cell proliferation assays. The antitumor efficacy was studied in mouse mammary carcinoma models (Her2/neu transgenic and 4T1-luc mammary cancers) treated with systemic recombinant protein with/without the depletion of myeloid-derived suppressor cells or intratumoral gene electrotransfer (GET). Systemic and regional changes of immune cells were examined by flow cytometry, and tumor specific IFN-γ release from immune cells was measured by ELISA assays.

Results IL-15cx shows superior in vivo bioactivity to expand CD8 T cells in comparison to an equimolar single chain IL-15. T-bet is partially involved in CD8 T cell expansion ex vivo and in vivo due to IL-15 or IL-15cx. Intraperitoneal administration of IL-15cx results in a moderate inhibition of breast cancer growth that is associated with an increase in the frequency of cytotoxic CD8 T cells and the improvement of their function. The depletion of myeloid-derived suppressor cells (MDSCs) has no impact on mouse breast cancer growth. IL-15cx treatment diminishes MDSCs in murine tumors. However, it also antagonizes the effects of depleting antibody. Intratumoral GET with plasmid IL-15/IL-15Rα leads to a long-term survival benefit in 4T1 mammary carcinoma model. An early increase of local cytotoxic cells correlates with GET treatment and an increase of long-term memory T cells results from animals with complete tumor regression.

Conclusions Systemic and local administration of IL-15cx shows two distinct therapeutic responses, a moderate tumor growth inhibition or heterogenous tumor regressions with survival improvement. Further studies are warranted to improve the efficacy of IL-15cx as an immunotherapy for breast cancer.

Acknowledgements This work was supported by funding from the National Cancer Institute grant R21 CA229939 to S. Guo and funding from the Thomas F. and Kate Miller Jeffress Memorial Trust to R. B. Smeltz.

Trial Registration N/A

Ethics Approval Experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at Old Dominion University (S. Guo) and by the IACUC at Virginia Commonwealth University (R.B. Smeltz).

References N/A

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.